EWM
RXRX icon

Elevatus Welath Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Elevatus Welath Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-342,567
Closed -$2.57M – 118
2024
Q2 		$2.57M Buy
342,567
+312,917
+1,055% +$2.73M 0.96% 37
2024
Q1 		$296K Buy
29,650
+5,000
+20% +$55.7K 0.12% 72
2023
Q4 		$243K Buy
+24,650
New +$176K 0.11% 75

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Elevatus Welath Management's RXRX Position: Q3 2024 in Review

Elevatus Welath Management sold out of Recursion Pharmaceuticals (RXRX) in Q3 2024, closing a stake of 342,567 shares — an estimated $2.57M sold.

Elevatus Welath Management first reported a position in RXRX in Q4 2023 and held it in 3 quarters. The position peaked at $2.57M in Q2 2024. 267 funds tracked by Wall St. Rank hold RXRX as of Q3 2024.

  • Elevatus Welath Management reported no remaining Recursion Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Elevatus Welath Management sold 342,567 Recursion Pharmaceuticals shares in Q3 2024, an estimated $2.57M.
  • Elevatus Welath Management first reported a position in Recursion Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Elevatus Welath Management's Recursion Pharmaceuticals position peaked at $2.57M in Q2 2024.
  • 267 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2024.

Based on Elevatus Welath Management's 13F filing for Q3 2024, filed 14 Nov 2024.